Phase 2 Multiple Sclerosis Trial, Recruiting NCT03207464 Sponsor: Brigham and Women's Hospital Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 2 Multiple Sclerosis Trial, Recruiting

NCT03207464
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Multiple Sclerosis (MS) and your disability level is not severely advanced (below a certain score on a standard MS disability scale)
  • You are between 18 and 70 years old (male or female)
  • You are willing to have PET and MRI brain scans as part of the study
  • You are willing and able to agree to participate by signing a consent form

Who may not be able to join:

  • You have a serious mental health condition such as schizophrenia, bipolar disorder, or post-traumatic stress disorder (PTSD)
  • You have another known brain or nervous system condition, a previous significant head injury, or a history of substance abuse
  • You are currently taking certain antidepressant medications, including tricyclic antidepressants, SNRIs, or NDRIs (confirm with trial site if you are unsure whether your medication falls into these categories)
  • You have other medical conditions that would make the study procedures unsafe for you (confirm with trial site)
  • You are pregnant, breastfeeding, trying to become pregnant, or think you might currently be pregnant
  • You experience claustrophobia (fear of enclosed spaces, such as an MRI scanner)
  • You have a medical implant in your body that is not safe to use with an MRI machine
  • You have taken steroid (corticosteroid) medications within the past four weeks

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Tarun Singhal, M.D., Brigham and Women's Hospital

Phone: 617-264-3043

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
10 October 2017
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

[C-11]Methylreboxetine area under the curve ratios

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov